DIRS.INFO The most relevant business & tech news

☆ GoodRx to offer Sanofi's insulin injection for only $35
▼ + stars: | 2023-10-19 | by ( ) www.reuters.com time to read: +1 min

A pharmacist holds a box of the drug Lantus SoloStar, made by Sanofi Pharmaceutical, at a pharmacy in Provo, Utah, U.S. January 9, 2020. This collaboration comes after Novo Nordisk (NOVOb.CO) , Eli Lilly (LLY.N) and Sanofi pledged in March to lower the list prices of many of their insulin products by 70%-78% later in the year or in 2024. Americans with insurance typically pay a fraction of the list prices for prescription drugs, but uninsured people sometimes have to pay the full price, forcing some to ration or skip taking their medicine. About 8.4 million of the 37 million people with diabetes in the U.S. use insulin, according to the American Diabetes Association. Reporting by Khushi Mandowara in Bengaluru; Editing by Shweta AgarwalOur Standards: The Thomson Reuters Trust Principles.

Persons: SoloStar, George Frey, GoodRx, Eli Lilly, Khushi, Shweta Agarwal Organizations: Sanofi Pharmaceutical, REUTERS, Sanofi, U.S ., Novo Nordisk, Novo, American Diabetes Association, Thomson Locations: Provo , Utah, U.S, Lilly, Bengaluru

☆ Merck KGaA says MS drug has blockbuster potential; key data expected in December
▼ + stars: | 2023-10-19 | by ( Ludwig Burger | ) www.reuters.com time to read: +2 min

Merck, seen as leading the race to win approval for a more targeted type of MS drug, said in April that U.S. regulators had paused enrolment of new patients into a trial testing the drug, evobrutinib, knocking the German drugmaker's share price. "The readout of our Phase 3 study is going to happen in December," she added of the pivotal study in the clinical trials process. Novartis (NOVN.S), also in the race, said in April that no signs of liver damage had been seen in trials testing its anti-inflammatory drug candidate remibrutinib so far. Roche (ROG.S) said in May that its BTK inhibitor against MS, reduced brain lesions associated with the disease in a mid-stage trial and that no new safety concerns had emerged. Reporting by Ludwig Burger Editing by Bill BerkrotOur Standards: The Thomson Reuters Trust Principles.

Persons: Germany's Merck, Belen Garijo, ROG.S, Ludwig Burger, Bill Berkrot Organizations: Germany's, Merck, U.S . Food, Drug Administration, Reuters, Rivals, Sanofi, Novartis, Thomson Locations: FRANKFURT, U.S, Darmstadt

☆ AstraZeneca shares fall as lung cancer drug trial data abstract disappoints
▼ + stars: | 2023-10-18 | by ( ) www.reuters.com time to read: +2 min

REUTERS/Phil Noble/File Photo Acquire Licensing RightsOct 18 (Reuters) - Shares in AstraZeneca (AZN.L) fell more than 4% on Wednesday after a data abstract on its experimental precision drug's use in lung cancer patients in a late-stage trial disappointed some analysts. Fernandez added that progression-free survival in lung cancer patients came in below expectations. Barclays analyst Emily Field also said in a note that safety looked better than expected for lung cancer patients and the data abstracts were "collectively positive" for AstraZeneca. London-listed shares of AstraZeneca were down 3.7% at 1219 GMT, while the broader STOXX Health Care (.SXDP) index was off 1%. Shares of AstraZeneca's Japanese partner Daiichi Sankyo (4568.T), which is jointly developing the cancer drug, closed 4.6% lower on Tuesday.

Persons: Phil Noble, datopotamab deruxtecan, Jefferies, Stephen Barker, Barker, Seamus Fernandez, Fernandez, Emily Field, GSK's, Danilo Masoni, Maggie Fick, Bhanvi, Shinjini Organizations: AstraZeneca, REUTERS, European Society for Medical, Friday, Guggeinheim, Barclays, AstraZeneca ., Thomson Locations: Macclesfield, Britain, Madrid, AstraZeneca . London, U.S, Milan, London, Bengaluru

Traders work on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., September 26, 2023. While the 30-year Treasury yield crossed above 5% for the first time since August 2007, the 10-year and five-year yields hit their highest since 2007. The CBOE volatility index (.VIX), Wall Street's "fear gauge", briefly hit a five-month high and topped its long-term average of 20. A day after U.S. job openings unexpectedly rose in August, investors will closely monitor September ADP National Employment data at 8:15 a.m. Reporting by Ankika Biswas and Shashwat Chauhan in Bengaluru; Editing by Shounak DasguptaOur Standards: The Thomson Reuters Trust Principles.

Persons: Brendan McDermid, Kevin McCarthy, Mark Haefele, Haefele, Austan Goolsbee, Michelle Bowman, Eli Lilly, LLY.N, Mike Mason, Ankika Biswas, Shashwat Chauhan, Shounak Dasgupta Organizations: New York Stock Exchange, REUTERS, Apple, U.S . House Republicans, Treasury, Microsoft, Nvidia, Dow e, Nasdaq, Federal, UBS Global Wealth, Institute, Supply, PMI, Chicago, Traders, Dow, Intel, Thomson Locations: New York City, U.S, Bengaluru

Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. The concerns over the limited use of the drug, however, dragged the shares down to settle 8% lower. That makes the label narrower than that in Europe, which allows use in all adults with late-onset Pompe disease. At least one analyst said the drug's label, which restricts its use only to switch patients, weighed on the drugmaker's shares. Amicus said it would launch the therapy immediately in the U.S. with a list price of around $650,000 for a patient weighing about 70 kilograms.

Persons: Andrew Kelly, Needham, Gil Blum, Sriparna Roy, Shinjini Ganguli, Sriraj, Shweta Agarwal Organizations: Food and Drug Administration, FDA, REUTERS, Amicus Therapeutics, U.S . Food, Sanofi, Amicus, Thomson Locations: White Oak , Maryland, U.S, Europe, Sanofi, Bengaluru

☆ Here's a rapid-fire update on all 35 stocks in the Club's portfolio, including a new buy
▼ + stars: | 2023-09-21 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +12 min

Here's a rapid-fire update on all stocks in Jim Cramer's Charitable Trust, the portfolio we use for the CNBC Investing Club. But for investors who haven't bought into its steep pullback, it's reasonable to buy some shares at current levels around $146.50 each. Unless you believe inflation is going to keep raging, making Microsoft's price-to-earnings multiple too high, then this stock is a buy. Nvidia (NVDA): Investors who don't own Nvidia yet should use its recent weakness to start a position, Jim said. Pioneer Natural Resources (PXD): We decided to buy additional Pioneer shares Thursday as the stock fell more than 2%.

Persons: Jim Cramer's, Jim, Amazon, he's, could've, We're, Jefferies, it's, we'd, Dupont De Nemours, That's, Dupont, Danaher, Bob Iger, Estee Lauder, haven't, Locker, Marry Dillon, Leqembi, Eli Lilly's donanemab, Vimal Kapur, Eli Lilly, Mark Zuckerberg, Morgan Stanley, Morgan, we're, James Gorman, Oracle, Safra Catz, Elliott, Stanley Black, Decker, TJ Maxx, Wells Fargo, Wells, Wynn, Jim Cramer Rob Kim Organizations: Jim Cramer's Charitable Trust, CNBC, Club, Apple, Web Services, Broadcom, Google, Bausch Health, Health, Caterpillar, Costco Wholesale, Costco, Coterra Energy, Coterra, Emerson, National Instruments, Ford, United Auto Workers, GE Healthcare, Honeywell International, Honeywell, Linde, LIN, Mounjaro, Meta, Microsoft, Nvidia, Oracle, Palo Alto Networks, Procter & Gamble, Natural Resources, Starbucks, Constellation Brands, Constellation, Elliott Management, TJX, Marshalls, Wynn Resorts, WYNN Locations: China, India, Dupont, Emerson, Meta, Beijing, HomeGoods

☆ Novo Nordisk owner invests $290 million in energy transition fund
▼ + stars: | 2023-09-14 | by ( Maggie Fick | ) www.reuters.com time to read: +2 min

FILE PHOTO-A coffee machine featuring Novo Nordisk logo is seen at the company headquarters in Copenhagen, Denmark, February 5, 2020. REUTERS/Jacob Gronholt-Pedersen/File Photo Acquire Licensing RightsCompanies Novo Nordisk A/S FollowLONDON, Sept 14 (Reuters) - The controlling shareholder in drugmaker Novo Nordisk on Thursday announced a major investment in a new energy transition fund as it expands its portfolio beyond health. Novo Holdings controls 76% of the votes in Denmark's Novo Nordisk (NOVOb.CO), which became Europe's most valuable company last week on the back of soaring profits from its weight-loss drug Wegovy and type 2 diabetes drug Ozempic. Novo Holdings' capital to invest is burgeoning on Novo Nordisk's financial performance. Novo Holdings is wholly owned by the Novo Nordisk Foundation, which lists its aims as providing "a stable basis for the commercial and research activities conducted by the companies within the Novo Group", of which Novo Nordisk is the largest, and supporting "scientific, humanitarian, and social purposes."

Persons: Jacob Gronholt, Pedersen, Morten Beck Jorgensen, " Jorgensen, Maggie Fick, Amanda Cooper, Elaine Hardcastle Organizations: Novo Nordisk, REUTERS, drugmaker Novo Nordisk, Novo Holdings, Denmark's, Denmark's Novo Nordisk, Holdings, Glentra Capital, Glentra, Reuters, Novo, Novo Nordisk Foundation, Thomson Locations: Copenhagen, Denmark, drugmaker Novo, Denmark's Novo, Glentra Capital

☆ Investors can find income in these quality stocks, Berenberg says
▼ + stars: | 2023-09-12 | by ( Michelle Fox | ) www.cnbc.com time to read: +3 min

Dividends may be harder to find these days, and that means investors should be discerning as they hunt for an income strategy, according to Berenberg. In fact, as the economy slows, investors can turn to dividend stocks to play defense. The largest company, Exxon Mobil , has a 12-month forward dividend yield of 3.3% and a surplus free-cash-flow yield of 4%, Stubbs said. It has a 4.7% 12-month forward dividend yield and a surplus free-cash-flow yield of 2.2%. It has a 12-month forward dividend yield of 5.8% and a 5% surplus free-cash-flow yield, according to Berenberg.

Persons: Jonathan Stubbs, Stubbs, Berenberg, Darren Woods, CNBC's, Eli Lilly, Ford, — CNBC's Michael Bloom Organizations: P Global Market Intelligence, Exxon Mobil, Pfizer, Food and Drug Administration, Novo Nordisk, Ford Locations: U.S, Canada

☆ AstraZeneca shares fall 3.6% to 7-1/2 week low
▼ + stars: | 2023-09-11 | by ( ) www.reuters.com time to read: 1 min

The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange, U.S., April 8, 2019. REUTERS/Brendan McDermid/File Photo Acquire Licensing RightsLONDON, Sept 11 (Reuters) - Shares in London-listed drugmaker AstraZeneca (AZN.L) declined as much as 3.6% on Monday, falling to their lowest since July 19. Reuters could not independently verify the information. AstraZeneca declined to comment on the report. Reporting by Samuel Indyk and Maggie Fick; Editing by Amanda CooperOur Standards: The Thomson Reuters Trust Principles.

Persons: Brendan McDermid, Pascal Soriot, Samuel Indyk, Maggie Fick, Amanda Cooper Organizations: AstraZeneca, New York Stock Exchange, REUTERS, Traders, Reuters, Thomson Locations: London

☆ AstraZeneca's Tagrisso-chemo combo results raise bar for J&J cancer drug-analysts
▼ + stars: | 2023-09-11 | by ( Maggie Fick | ) www.reuters.com time to read: +2 min

LONDON, Sept 11 (Reuters) - Data released on Monday by AstraZeneca (AZN.L) from a late-stage trial combining its blockbuster cancer drug Tagrisso with chemotherapy to treat a type of lung cancer raises the bar for Johnson & Johnson's (JNJ.N) rival treatment, analysts said. A brief summary from the Phase 3 trial, called FLAURA2, was released in May, and the detailed data was presented on Monday in Singapore at the World Conference on Lung Cancer. The FLAURA2 trial showed that when adding chemotherapy to Tagrisso, the risk of disease progression or death is reduced by 38% when compared to Tagrisso alone. "With the strong FLAURA-2 data in hand and likely included in treatment guidelines soon, the hurdle is now pretty high in our view for MARIPOSA," the UBS note read. Barclays analysts said the FLAURA2 trial data presented on Monday included doctor and patient surveys that showed a strong preference for the convenience of a single therapy compared with combinations.

Persons: Johnson, Pascal Soriot, Michel Demare, Soriot, Maggie Fick, Emelia Sithole Organizations: AstraZeneca, Lung Cancer, Barclays, UBS, Reuters, Thomson Locations: Singapore, British, MARIPOSA

☆ AstraZeneca shares fall 4% to 7-1/2 week low
▼ + stars: | 2023-09-11 | by ( ) www.reuters.com time to read: +1 min

The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange, U.S., April 8, 2019. REUTERS/Brendan McDermid/File Photo Acquire Licensing RightsCompanies AstraZeneca PLC FollowLONDON, Sept 11 (Reuters) - Shares in London-listed drugmaker AstraZeneca (AZN.L) fell more than 4% on Monday, sliding to their lowest since July 19. An AstraZeneca spokesperson declined to comment on the report. Two of the analysts and the shareholder also mentioned that an article published on Monday in Britain's Times newspaper could have affected the shares, though it appeared to contradict the Mail on Sunday report. The Times' article focused on the retirement of Mene Pangalos, the long-time biopharmaceuticals head of research at AstraZeneca, which was announced in July.

Persons: Brendan McDermid, Pascal Soriot, Mene Pangalos, Pangalos, Pascal, Maggie Fick, Samuel Indyk, Amanda Cooper, Tomasz Janowski Organizations: AstraZeneca, New York Stock Exchange, REUTERS, drugmaker's, Reuters, Britain's Times, Times, Thomson Locations: London

☆ Miners boost FTSE 100 on China optimism; Vistry jumps
▼ + stars: | 2023-09-11 | by ( ) www.reuters.com time to read: +1 min

Signage for the London Stock Exchange Group is seen outside of offices in Canary Wharf in London, Britain, August 3, 2023. REUTERS/Toby Melville/File Photo Acquire Licensing RightsSummaryCompanies FTSE 100 up 0.6%, FTSE 250 adds 0.4%Sept 11 (Reuters) - The UK's exporter-heavy FTSE 100 index opened higher on Monday boosted by miners after positive China data signalled stability in the world's second-largest economy, while Vistry shares jumped after the homebuilder kept its annual profit outlook. The blue-chip FTSE 100 index (.FTSE) rose 0.6% in early trade, while the mid-cap FTSE 250 index (.FTMC) was up 0.4%. Vistry Group (VTYV.L) jumped 14.4% after the British homebuilder said it would merge its affordable-housing business 'Partnerships' with its Housebuilding operations, while maintaining its annual profit forecast. Reporting by Siddarth S in Bengaluru; Editing by Rashmi AichOur Standards: The Thomson Reuters Trust Principles.

Persons: Toby Melville, British homebuilder, Pascal Soriot, Siddarth, Rashmi Organizations: London Stock Exchange, REUTERS, Vistry, AstraZeneca, The Mail, Barclays, Reuters, Thomson Locations: Canary Wharf, London, Britain, China, British, Bengaluru

Wegovy is the first-to-market in a new class of highly effective weight-loss drugs. The self-injection drug has transformed the fortunes of Novo, whose shares have surged about 165% since Wegovy's U.S. launch two years ago. The lion's share may be claimed by frontrunners Novo and its U.S. rival Eli Lilly and Co (LLY.N). Last month, Novo launched Wegovy in Germany, its first big European market. Reporting by Maggie Fick and Jacob Gronholt-Pedersen Editing by Josephine Mason and Mark PotterOur Standards: The Thomson Reuters Trust Principles.

Persons: Novo Nordisk Lars Fruergaard Jorgensen, LUDOVIC MARIN, Lars Fruergaard Jorgensen's, Jorgensen, Eli Lilly, Wegovy, Novo, Maggie Fick, Jacob Gronholt, Pedersen, Josephine Mason, Mark Potter Organizations: Novo Nordisk, Chateau, BMI, Reuters, frontrunners Novo, Pfizer, Thomson Locations: Versailles, Paris, COPENHAGEN, Europe, Danish, United States, Denmark, Norway, Brussels, Wegovy, Germany

☆ Mallinckrodt second bankruptcy would cut $1 billion from opioid settlement
▼ + stars: | 2023-08-23 | by ( ) www.reuters.com time to read: +2 min

The agreement announced Wednesday would reduce Mallinckrodt's debt by about $1.9 billion and cancel existing equity shares. The new deal would leave opioid creditors with $1 billion less than the $1.7 billion settlement that Mallinckrodt agreed to pay as part of its 2022 exit from the company's earlier bankruptcy. Mallinckrodt failed to make a $200 million payment to the opioid trust due in June, prompting the company to launch a negotiation with its stakeholders. Mallinckrodt said that its current level of creditor support should allow the company to complete its second bankruptcy by the end of 2023. Drug manufacturers, drug distributors and pharmacy chains have agreed to pay more than $50 billion in settlements to resolve lawsuits related to the U.S. opioid crisis.

Persons: Hydrocodine, Mallinckrodt, George Frey, Siggi Olafsson, Pratik Jain, Mariam Sunny, Khushi, Dietrich Knauth, Maju Samuel, Shinjini Ganguli, Alexia Garamfalvi Organizations: REUTERS, Thomson Locations: Provo , Utah, U.S, Ireland, Bengaluru, New York

A selection of injector pens for the Wegovy weight loss drug are shown in this photo illustration in Chicago, Illinois, U.S., March 31, 2023. The study called SELECT involved 17,500 patients aged 45 years or older with no prior history of diabetes and started almost five years ago testing if the weekly injection has medical benefits. The landmark trial data shows Wegovy has "the potential to change how obesity is regarded and treated," said Martin Holst Lange, executive vice president for development at Novo Nordisk, in a statement. Novo Nordisk said it expects to file for regulatory approvals of a label indication expansion for the weekly injection in the United States and European Union this year. The detailed results from the trial will be presented at a scientific conference later in 2023.

Persons: Jim Vondruska, Wegovy, Danish drugmaker, That's, Martin Holst Lange, Soren Lontoft Hansen, Novo, Maggie Fick, Nikolaj Skydsgaard, Josephine Mason, Sharon Singleton, Kirsten Donovan Organizations: REUTERS, COPENHAGEN, Novo Nordisk, Nordisk, European Union, World Health Organization, Barclays, Thomson Locations: Chicago , Illinois, U.S, LONDON, Danish, Europe's, United States, Europe, European, Norway, Denmark, Germany, Norwegian

In a filing to Shanghai's stock exchange, CanSino said it would manufacture and supply unspecified mRNA products to AstraZeneca. AstraZeneca said the deal would support investigational mRNA vaccines in its early pipeline. The country approved in March its first homegrown mRNA vaccine against COVID, developed by CSPC Pharmaceutical Group (1093.HK). CanSino has been working on its own mRNA COVID vaccine, and said in February it was in discussion with Chinese regulators around the protocol for a late-stage study for its COVID mRNA booster vaccine, CS-2034. It also comes after vaccine maker Moderna (MRNA.O), which has said that it was keen to sell its mRNA vaccine to China, announced a deal last month to develop and manufacture mRNA medicines in the country.

Persons: Dado Ruvic, Biologics, CanSino, Wang Wentao, Casey Hall, Ludwig Burger, Miyoung Kim, Mark Potter, Himani Organizations: AstraZeneca, REUTERS, HK, CSPC Pharmaceutical, CS, Communist Party, China's Commerce, Moderna, Thomson Locations: Swedish, China, Frankfurt

☆ Morgan Stanley sees Eli Lilly shares rallying on data showing heart benefit of Novo's obesity drug
▼ + stars: | 2023-08-08 | by ( Yun Li | ) www.cnbc.com time to read: +1 min

Danish drugmaker Novo Nordisk 's promising data on its obesity drug Wegovy should benefit Eli Lilly 's pipeline and its stock, according to Morgan Stanley. Shares of Novo Nordisk soared 15% in early trading Tuesday after late-stage trial data showed that Wegovy reduced the risk of major cardiovascular events, such as heart attacks or strokes, by 20%, compared with a placebo. "This is above our expectations and our prior analysis," Morgan Stanley analyst Terence Flynn said. Flynn has an overweight rating on Eli Lilly and a $560 12-month price target, which would translate into a 23% gain from Monday's close of $454.08. Eli Lilly raised its full-year guidance Tuesday as second-quarter profit jumped 85% from the same period a year ago on strong sales resulting from its drug pipeline.

Persons: Eli Lilly, Morgan Stanley, Terence Flynn, Eli Lilly's, Flynn, — CNBC's Michael Bloom Organizations: Nordisk, Novo Nordisk Locations: Indianapolis

Traders work on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., July 20, 2023. Uber (UBER.N) fell after the ride-hailing company missed second-quarter revenue expectations. Arista Networks (ANET.N) stocks rose as the network gear maker forecast quarterly revenue above estimates after delivering better-than-expected results. According to preliminary data, the S&P 500 (.SPX) lost 12.25 points, or 0.26%, to end at 4,576.94 points, while the Nasdaq Composite (.IXIC) lost 62.11 points, or 0.43%, to 14,284.20. JetBlue Airways (JBLU.O) stocks dropped after it lowered its annual profit forecast due to a hit from the termination of its revenue-sharing deal with American Airlines (AAL.O).

Persons: Brendan McDermid, It's, Scott Ladner, Echo Wang, Johann M Cherian, Vinay Dwivedi, Richard Chang Organizations: New York Stock Exchange, REUTERS, PMI, Dow, Nasdaq, Horizon Investments, Caterpillar, Pfizer, Treasury, Arista Networks, Dow Jones, Norwegian Cruise, JetBlue Airways, American Airlines, Thomson Locations: New York City, U.S, New York, Bengaluru

Second-quarter earnings for S&P 500 companies are estimated to have fallen 6.4% year-over-year, Refinitiv data through Friday showed. Citigroup raised its 2023-end and mid-2024 S&P 500 targets to 4,600 and 5,000, respectively, to reflect a higher possibility of a soft landing. According to preliminary data, the S&P 500 (.SPX) gained 7.64 points, or 0.17%, to end at 4,589.15 points, while the Nasdaq Composite (.IXIC) gained 29.37 points, or 0.21%, to 14,348.50. Nearly half of the top 11 S&P 500 sectors posted gains, led by a rise in energy stocks (.SPNY). Adobe (ADBE.O) stocks rose, outperforming tech peers, after Morgan Stanley raised its rating to "overweight" on the photoshop maker.

Persons: Dow, Ross Mayfield, Austan Goolsbee, Jay Hatfield, Johnson, Morgan Stanley, Echo Wang, Johann M Cherian, Vinay Dwivedi, Richard Chang Organizations: Citigroup, Nasdaq, Amazon.com, Apple, Baird, Intel, Lam Research, Chicago Fed, Dow Jones, Infrastructure Capital Advisors, SoFi Technologies, ON Semiconductor, Dow, Johnson, Adobe, Thomson, & & ' Locations: Louisville , Kentucky, New York, U.S, Bengaluru

Second-quarter earnings for S&P 500 companies are estimated to have fallen 6.4% year-over-year, Refinitiv data through Friday showed. The tech-heavy Nasdaq led Wall Street higher last week as megacap growth companies such as Alphabet (GOOGL.O), Meta Platforms (META.O) as well as chipmakers Intel (INTC.O) and Lam Research (LRCX.O) posted strong quarterly earnings. Citigroup raised its 2023-end and mid-2024 S&P 500 targets to 4,600 and 5,000, respectively, to reflect a higher possibility of a soft landing. Eight of the top 11 S&P 500 sectors posted gains, led by a 2% rise in energy stocks (.SPNY). The S&P 500 posted 27 new 52-week highs and one new low; the Nasdaq Composite recorded 95 new highs and 57 new lows.

Persons: Ross Mayfield, Austan Goolsbee, Jay Hatfield, Johnson, Morgan Stanley, decliners, Echo Wang, Johann M Cherian, Vinay Dwivedi, Richard Chang Organizations: Citigroup, Dow, Nasdaq, Amazon.com, Apple, Baird, Intel, Lam Research, Chicago Fed, Dow Jones, Infrastructure Capital Advisors, Financial, SoFi Technologies, ON Semiconductor, Johnson, Adobe, NYSE, Thomson, & & ' Locations: Louisville , Kentucky, New York, U.S, Bengaluru

Second-quarter earnings for S&P 500 companies are now estimated to have fallen 6.4% year-over-year, according to Refinitiv data. Citigroup raised its 2023-end and mid-2024 S&P 500 targets to 4,600 and 5,000, respectively, to reflect a higher possibility of a soft landing. Seven of the top 11 S&P 500 sectors gained, led by a 2.0% rise in energy stocks (.SPNY). The S&P index recorded 25 new 52-week highs and no new low, while the Nasdaq recorded 71 new highs and 37 new lows. Reporting by Johann M Cherian and Bansari Mayur Kamdar in Bengaluru Editing by Vinay DwivediOur Standards: The Thomson Reuters Trust Principles.

Persons: Chris Zaccarelli, Austan Goolsbee, Johnson, Morgan Stanley, Johann M Cherian, Vinay Dwivedi Organizations: Citigroup, Dow, Nasdaq, Apple, AMD, Independent, Alliance, Microsoft, Intel, Lam Research, Chicago Fed, Dow Jones, Financial, SoFi Technologies, ON Semiconductor, Johnson, UBS, Adobe, NYSE, Thomson, & & ' Locations: U.S, Xpeng, Bengaluru

FRANKFURT, July 29 (Reuters) - Novo Nordisk has launched blockbuster weight-loss drug Wegovy in Germany, its first big European market, hoping Germans will pay hundreds of euros out of pocket for a drug that public health insurance plans are so far barred from covering. The Danish drugmaker's share price has more than doubled in the two years since the drug debuted, turning Novo (NOVOb.CO) into Europe's second-most-valuable listed company after LVMH. Among major providers, Allianz (ALVG.DE) says it will pay if a physician diagnoses a medical need, while Debeka said its plans exclude weight-loss treatments. Novo is ramping up production to meet soaring demand in the United States, where the drug sells for as much as $1,350 a month. Doctors say many Germans seeking to lose weight have already used Ozempic, a diabetes drug also made by Novo that is a lower dose version of the same ingredient as Wegovy.

Persons: Wegovy, Debeka, Robert Koch, Ludwig Burger, Maggie Fick Organizations: Novo Nordisk, Novo, LVMH, Allianz, European Union, Robert Koch Institute, Thomson Locations: FRANKFURT, Germany, United States, Europe, Norway, Denmark, Danish, Novo, Wegovy, Frankfurt, London

SummaryCompanies Plans to file trial data with FDAComments sooth some investor concernsAbsence of "clinically meaningful" in interim trial data worried investorsLONDON, July 28 (Reuters) - AstraZeneca Chief Executive Pascal Soriot said on Friday the company is "very encouraged" by interim data from a key lung cancer drug trial, but he did not explain why the company had not declared results as "clinically meaningful". The drugmaker's (AZN.L) shares fell by as much as 8% earlier this month after the company released interim data from the late-stage clinical trial called TROPION-Lung01 testing an experimental precision drug called datopotamab deruxtecan. Speaking to media on Friday after the company released better-than-expected quarterly results, Soriot said people would understand when full results are released why the company did not use that description, but he did not comment further. The company said on Friday it will continue with its plan to file data from the trial with the U.S. Food and Drug Administration (FDA), soothing some investor concerns. In a briefing with analysts, Susan Galbraith, executive vice president of oncology R&D, said the FDA response to the data so far had been "encouraging".

Persons: Pascal Soriot, Soriot, Susan Galbraith, Maggie Fick, Josephine Mason, David Evans, Susan Fenton Organizations: LONDON, AstraZeneca, U.S . Food, Drug Administration, FDA, U.S, Thomson

July 21 (Reuters) - Pfizer Inc(PFE.N) CEO Albert Bourla said on Friday that tornado damage this week had almost completely destroyed the drugmaker's warehouse at its Rocky Mount, North Carolina, plant, but that production facilities there do not seem to have suffered damage. "It appears that most of the damage sustained at the site was at our warehouse ... the facilities that are producing, (it) doesn't seem that they have suffered any damage." In the meantime, the company is working to identify alternative manufacturing locations for production around the U.S. Nearly 25% of Pfizer's sterile injectables used in U.S. hospitals are produced there, according to the company's website. "There are so many shortages already," said Erin Fox, senior director of drug information at University of Utah Health.

Persons: Albert Bourla, Bourla, Soumi Saha, Saha, Erin Fox, Lisa Mulloy, David Ljunggren, Michael Erman, Rami Ayyub, Doina Organizations: Pfizer Inc, Engineers, U.S, Products, Premier Inc, American Society of Health, System Pharmacists, Pfizer, University of Utah Health, Thomson Locations: North Carolina, Rocky, U.S

☆ UBS upgrades Big Pharma stock after shares drop on poor drug results
▼ + stars: | 2023-07-13 | by ( Ganesh Rao | ) www.cnbc.com time to read: +3 min

UBS upgraded AstraZeneca 's stock to a "buy" rating despite the drugmaker's trial of a lung cancer medication recently delivering poor results. The investment bank said the subsequent drop in the pharma giant's stock price now meant that "investors can come back to the stock for the performance of in-market products." London-listed shares of AstraZeneca dropped by 8% in a single day, the most in years, after releasing the results of the "TropionLung01" trial for drug candidate "Dato-DXd." UBS expects shares of AstraZeneca to rise by 27% to £13 ($16.8) a share over the next 12 months. These include Imfinzi, a drug for bile duct or gallbladder cancer, and Tagrisso, a treatment for non-small cell lung cancer in adults.

Persons: Michael Leuchten, UBS Michael Leuchten AZN Organizations: UBS, AstraZeneca, pharma, DXd, FDA, Johnson Locations: London, Swiss, Tagrisso

Search resuls for: "drugmaker's"

25 mentions found